News Column

New Findings on Blood Proteins Discussed by Researchers at Sinhgad College of Pharmacy [Preparation and characterization of rivastigmine loaded human...

August 29, 2014



New Findings on Blood Proteins Discussed by Researchers at Sinhgad College of Pharmacy [Preparation and characterization of rivastigmine loaded human serum albumin (HSA) nanoparticles]

By a News Reporter-Staff News Editor at Drug Week -- Research findings on Proteins are discussed in a new report. According to news originating from Maharashtra, India, by NewsRx correspondents, research stated, "The aim of the present study was to develop and characterize rivastigmine loaded Human Serum Albumin (HSA) nanoparticles (NPs) for sustained release. Rivastigmine tartrate (RT) is a short acting cholinesterase inhibitor (ChEI) used for Alzheimer's disease (AD)."

Our news journalists obtained a quote from the research from the Sinhgad College of Pharmacy, "In the present study sustained release nanoparticulate formulation of RT was prepared, optimized (using 32 factorial design) and characterized (using biodegradable polymer HSA as a carrier). HSA NPs were prepared by desolvation-crosslinking technique using ethanol with variable drug/polymer ratios (1:1, 1:2, 1:3, and 1:5) and using glutaraldehyde as a crosslinking agent. All prepared nanoparticles were coated with polysorbate-80 to facilitate brain targeting via endocytosis. Effect of key formulation variables on particle size (PS) and percentage drug entrapment (PDE) of NPs was studied by using 32 factorial design. Among different ratios studied, 1:2 showed minimum PS of 83.71 4.2 nm with highest PDE of 81.46 0.76 %. FTIR interpretation showed that there is no interaction between the drug and excipients used, DSC thermograms indicated that RT was dispersed as an amorphous state in HSA NPs. SEM studies indicated that the drug was completely entrapped in HSA NPs. In vitro studies showed 55.59 3.80% release of drug from HSA NPs in 12 h."

According to the news editors, the research concluded: "The experimental results showed the suitability of HSA nanoparticles as a potential carrier for providing sustained delivery of RT."

For more information on this research see: Preparation and characterization of rivastigmine loaded human serum albumin (HSA) nanoparticles. Current Drug Delivery, 2014;11(3):359-70. (Bentham Science Publishers - www.benthamscience.com; Current Drug Delivery - www.benthamscience.com/cdd/index.htm)

The news correspondents report that additional information may be obtained from A.M. Avachat, Dept. of Pharmaceutics, Sinhgad College of Pharmacy, Vadgaon (Bk), Pune-411041, Maharashtra, India. Additional authors for this research include Y.M. Oswal, K.N. Gujar and R.D Shah (see also Proteins).

Keywords for this news article include: Asia, India, Maharashtra, Nanoparticle, Serum Albumin, Blood Proteins, Nanotechnology, Acute Phase Proteins, Emerging Technologies.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Drug Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters